NASDAQ
6.53USD
+2.33 (+55.48%)
We have scored 5 news catalysts on Lifecore Biomedical, Inc. (LFCR) over the past 12 months. The biggest single-day move next to one of them came Sep 28, 2026, when LFCR closed +57.7%: “Lifecore Biomedical to be Acquired by Webster Equity Partners”. Coverage across the window leans negative (average ticker sentiment −0.12). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
247.6M
P/E
—
EPS
—
Beta
1.08
52W range
3.63-8.98
Day range
6.40–6.61
Open
6.52
Prev close
4.20
Volume
846.5K
Avg volume
173.4K
Dividend
0.00
IPO
1996-02-15
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lifecore Biomedical, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LFCR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
